• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
ProMetic Life Sciences Inc. - Product Pipeline Review - Q4 2010 - Product Image

ProMetic Life Sciences Inc. - Product Pipeline Review - Q4 2010

  • Published: December 2010
  • Region: Global
  • 42 pages
  • Global Markets Direct

ProMetic Life Sciences Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “ProMetic Life Sciences Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ProMetic Life Sciences Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ProMetic Life Sciences Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
ProMetic Life Sciences Inc. Snapshot
ProMetic Life Sciences Inc. Overview
Key Information
Key Facts
ProMetic Life Sciences Inc. – Research and Development Overview
Key Therapeutic Areas
ProMetic Life Sciences Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ProMetic Life Sciences Inc. – Pipeline Products Glance
ProMetic Life Sciences Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
ProMetic Life Sciences Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ProMetic Life Sciences Inc. – Drug Profiles
PBI-1393
Product Description
Mechanism of Action
R&D Progress
PBI-1402
Product Description
Mechanism of Action
R&D Progress
PBI-0110
Product Description
Mechanism of Action
R&D Progress
PBI-1737
Product Description
Mechanism of Action
R&D Progress
ProMetic Life Sciences Inc. – Pipeline Analysis
ProMetic Life Sciences Inc. – Pipeline Products by Therapeutic Class
ProMetic Life Sciences Inc. Pipeline Products By Target
ProMetic Life Sciences Inc. – Pipeline Products by Route of Administration
ProMetic Life Sciences Inc. – Pipeline Products by Molecule Type
ProMetic Life Sciences Inc. – Recent Pipeline Updates
ProMetic Life Sciences Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 11, 2009: ProMetic Life Sciences Inc Discusses Development Of PBI-1402 With The U.S. Food and Drug Administration
Apr 17, 2008: Prometic Presents Preclinical Data For Prostate And Pancreatic Cancer At The AACR Meeting
Dec 10, 2007: Phase II Trial Of ProMetic’s PBI-1402 Shows Significantly Increased Red Blood Cell Count And Hemoglobin In Chemotherapy-Induced Anemia Patients
Jan 30, 2007: Prometic Completes Preclinical Toxicology Studies Of PBI-1393 In Support Of Offshore Clinical Trial For Advanced Cervical Cancer
Oct 08, 2004: Prometics' Phase II misses in atopic dermatitis.
Oct 08, 2004: Prometics' Phase II misses in atopic dermatitis.
Oct 08, 2004: Prometics' Phase II misses in atopic dermatitis.
Financial Deals Landscape
ProMetic Life Sciences Inc., Deals Volume Summary, 2004 to YTD 2010
ProMetic Life Sciences Inc., Deals Summary By Region, 2004 to YTD 2010
ProMetic Life Sciences Inc., Deals Summary, 2004 to YTD 2010
ProMetic Life Sciences Inc. Detailed Deal Summary
Acquisition
ProMetic Life Sciences Acquires Additional 51% Stake In Pathogen Removal And Diagnostic Technologies From American Red Cross
Equity Offering
ProMetic Completes Private Placement Of $7 Million
ProMetic Life Sciences Completes Private Placement Of $7.9 Million
Novozymes Enters Into Co-Marketing Agreement With ProMetic Life Sciences
ProMetic Life Sciences Enters Into Co-Development Agreement With Abraxis BioScience
ProMetic Life Sciences Signs Co-Development Agreement With Octapharma
Licensing Agreements
Abraxis Enters Into License Agreement With ProMetic Life Sciences
Nabi Biopharmaceuticals Enters Into Agreement With ProMetic Life Sciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS